BioSpace News Archive

The company’s PURE EP™ System is currently installed in six medical centers across the country Evaluation installations are growing and provide a strong foundation for commercial efforts in 2021 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac s

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®. Orphan drug status (ODS) is available to medicinal products that treat conditions affecting no more than 5 out of 10,000

CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for Medicare and Medicaid Services (CMS) granted approval for a transitional pass-through (TPT) payment for BAROSTIM Therapy as part of the 2021 Outpatient Prospective Payment System (OPPS) Final Rule issued December 2, 202

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), and Nantes University Hospital (CHU de Nantes) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethics Committee (CPP) approved the initiation of a Phase 1/2 trial evaluating first administration of FR104

The Montreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of TG4001, a HPV16 targeted therapeutic vaccine, in combination with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies at ESMO Immuno-Oncology Virtual Congress 2020, December 9-12, 2020.

Therap is announcing the release of its interface to Sandata, DHCF’s mandated EVV data aggregator.

Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE).

TheraCell Inc., a leading allograft solution company, today announced that it has expanded its licensing agreement with Australia’s leading tissue bank, Australian Biotechnologies, to include the exclusive rights to produce and market a comprehensive portfolio of demineralized fiber graft solutions for the Australian and New Zealand markets.

PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™ (lumasiran)